| 09:00-09:40 | Plenary 3: Genome Editing |
|---|---|
| 09:00-09:40 | PL03 Organellar DNA Editing in Vitro and in Vivo Jin-Soo Kim (KAIST, Korea) |
| 09:40-10:55 | Session 5. RNA & Genome Editing |
|---|---|
| 09:40-10:05 | S05-1 Wensheng Wei (Peking University, China) |
| 10:05-10:30 | S05-2 High-Resolution RNA Knockdown Profiles of Small RNA and Cas13 Systems S. Chul Kwon (The University of Hong Kong, Hong Kong, China) |
| 10:30-10:55 | S05-3 Seung Ryul Han (Rznomics, Korea) |
| 11:15-12:15 | Session 6. Short Talks (Selected from Abstracts) |
|---|---|
| 11:15-11:25 | S06-1 Enhancing Translational Validity: Integrating Welfare, Behavioral Enrichment, and the 3Rs into Non-Human Primate Models for Oligonucleotide Therapeutics Development Hanna Suh (Korea Institute of Toxicology, Korea) |
| 11:25-11:35 | S06-2 TBD |
| 11:35-11:45 | S06-3 TBD |
| 11:45-11:55 | S06-4 TBD |
| 11:55-12:05 | S06-5 TBD |
| 12:05-12:15 | S06-6 TBD |
| 13:15-13:55 | Plenary 4: Aptamer Therapeutics & Clinical Translation |
|---|---|
| 13:15-13:55 | PL04 Preclinical and Clinical Development of Anticoagulant and Thrombolytic Aptamers and Reversal Agents Bruce Sullenger (Duke University, USA) |
| 13:55-15:15 | Session 7. Aptamers & ASO |
|---|---|
| 13:55-14:20 | S07-1 Novel DNA Modality: Genetic Alphabet Expansion Ichiro Hirao (Xenolis Pte Ltd, Singapore) |
| 14:20-14:45 |
S07-2 Addressing Key Challenges in Oligonucleotide Therapeutics with Luxna Xeno Nucleic Acid (XNA) Technologies Ryohei Kajino (Luxna Biotech, Japan) |
| 14:45-15:00 |
S07-3 Brain Somatic Mosaicism: A Platform for RNA Therapeutic Target Discovery in Neurological Disorders Jeong Ho Lee (KAIST / Sovargen, Korea) |
| 15:00-15:15 | S07-4 Il-Hoan Oh (RegenInnopharm, Korea) |
| 15:35-17:15 | Session 8. Oligonucleotide Development — Tox, CMC & Regulatory |
|---|---|
| 15:35-16:00 | S08-1 Yogesh S. Sanghvi (Rasayan Inc., USA) |
| 16:00-16:25 | S08-2 The Impurity Puzzle: Connecting Process, Quality, and Regulatory Strategy Thomas Rupp (Thomas Rupp Consulting UG, Germany) |
| 16:25-16:50 | S08-3 Zilganersen in Alexander Disease: Translational Pharmacology, CNS Delivery, and Intrathecal Safety Tae-Won Kim (Ionis Pharmaceuticals, USA) |
| 16:50-17:15 | S08-4 From Chiral Monomers to Stereopure Oligonucleotides: Synthesis and NMR Characterization Ik-Hyeon Paik (Wave Life Sciences, USA) |